Your session is about to expire
← Back to Search
Chemo/Immunotherapy for Non-Small Cell Lung Cancer
Study Summary
This trial is comparing how well two groups of cancer patients respond to immunotherapy. One group has cancer that is not as advanced, and the other group has cancer that is more advanced. The goal is to show that the group with more advanced cancer does just as well as the other group when treated with immunotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.My blood tests show normal white blood cell and platelet counts.I have an autoimmune disease treated within the last 2 years.I haven't had chemotherapy or immunotherapy for my cancer, except possibly for early-stage treatment.I have had lung inflammation treated with steroids.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.My lung cancer cannot be removed by surgery and has no cure with standard treatments.I agree to use birth control during the study.I can take care of myself and am up and about more than half of my waking hours.You are expected to live for more than 3 months.My lung cancer has a specific mutation that requires targeted therapy.Your cancer must be visible on imaging tests according to specific guidelines.
- Group 1: Performance Status 0-1 Participants
- Group 2: Performance Status 2 Participants
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What additional trials have been undertaken in relation to Pembrolizumab?
"At present, 2031 Pembrolizumab studies are ongoing. Of those, 426 have reached the third phase of clinical trials. Shanghai is the epicentre for pembrolizumab research but there are nearly a hundred thousand sites globally conducting investigations into this medication's efficacy and safety."
Are enrollment slots still open for this research endeavor?
"According to clinicaltrials.gov, this trial is in search of new participants and has been since its inception on July 1st 2020. The listing was most recently modified on June 28th 2022."
What is the current capacity for participants in this research trial?
"Affirmative, according to the clinicaltrials.gov portal this trial is currently recruiting volunteers and has been doing so since July 1st 2020 - with the most recent update occurring June 28th 2021. The research team are looking for 80 participants from a single location."
What maladies is Pembrolizumab typically employed to alleviate?
"Pembrolizumab is primarily utilized to treat malignant neoplasms. Additionally, it can be effectively administered in patients with unresectable melanoma, microsatellite instability high, and those suffering from locally advanced nonsquamous non-small cell lung cancer."
What safety precautions should be taken when using Pembrolizumab?
"Pembrolizumab has been assessed to have a safety score of 2, as this is just a Phase 2 trial and therefore lacks evidence of efficacy."
Share this study with friends
Copy Link
Messenger